KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Goodwill (2020 - 2026)

AbCellera Biologics filings provide 7 years of Goodwill readings, the most recent being $47.8 million for Q1 2026.

  • Quarterly Goodwill changed 0.0% to $47.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $47.8 million through Mar 2026, changed 0.0% year-over-year, with the annual reading at $47.8 million for FY2025, 0.01% changed from the prior year.
  • Goodwill hit $47.8 million in Q1 2026 for AbCellera Biologics, roughly flat from $47.8 million in the prior quarter.
  • Across five years, Goodwill topped out at $47.8 million in Q1 2022 and bottomed at $47.8 million in Q4 2023.
  • Average Goodwill over 5 years is $47.8 million, with a median of $47.8 million recorded in 2022.
  • Peak annual rise in Goodwill hit 51.77% in 2022, while the deepest fall reached 3.34% in 2022.
  • AbCellera Biologics' Goodwill stood at $47.8 million in 2022, then fell by 0.01% to $47.8 million in 2023, then changed by 0.0% to $47.8 million in 2024, then rose by 0.01% to $47.8 million in 2025, then changed by 0.0% to $47.8 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Goodwill are $47.8 million (Q1 2026), $47.8 million (Q4 2025), and $47.8 million (Q3 2025).